Patients experience fevers for many reasons, but can they help physicians diagnose disease? Using modern technology and social media, Jonathan S. Hausmann, MD, is working to further the understanding of body temperatures…
Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…
Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…
Rheumatology Research Foundation Recognizes Donors of Merit
On Nov. 12, nearly 150 supporters of the Rheumatology Research Foundation gathered at the St. Regis Washington, D.C., for the Donors of Merit recognition dinner. This annual event honors those who contributed to the Foundation throughout the year. Foundation President Eric Matteson, MD, MPH, applauded leaders who have played an essential role in the Foundation’s success….
RISE Registry Promises to Improve Care & Research for Rheumatology
In 2014, the ACR launched the Rheumatology Informatics System for Effectiveness (RISE), a national electronic health record (EHR)-enabled registry. The goal: To help participating rheumatologists and practices leverage the new wave of big data created by the use of EHR, advance research and improve overall quality of care. A new analysis examines the RISE structure and the initial patient data collected by the registry…
Effect of Diet & Sodium Intake on Serum Uric Acid
Serum uric acid (UA) is an important factor in the causal pathway for gout. It has also been implicated as a potential risk factor and/or mediator of cardiovascular disease outcomes and mortality in a large number of observational studies. Although many of the clinical trials targeting serum UA reduction have focused on pharmacologic interventions, diet…
Systemic Corticosteroid Usage in Stage 4 Pulmonary Sarcoidosis Could Offer Little Benefit, Pose Significant Health Risk
Depending on stage, severity and rate of progression of disease, systemic corticosteroids are commonly used to treat pulmonary sarcoidosis. However, a review of the literature suggests they have limited usefulness in advanced stage IV pulmonary sarcoidosis. Once sarcoidosis has advanced to this degree, steroid use may unnecessarily expose a patient to life-threatening complications, as demonstrated…
Research Underscores Need to Assess Oral Health in Patients with Systemic Sclerosis
Oral health is not frequently considered within the sphere of a rheumatologist’s practice. However, recent results published by the Canadian Scleroderma Research Group (CSRG) point out the importance of assessing oral health in patients with systemic sclerosis (SSc). Result of 3-Year Grant Between 2008 and 2011, 163 patients with SSc and 231 controls were entered…
Rheumatology Patient, Investigator Reflect on Advancements in Lupus, Rheumatoid Arthritis Treatments
In 1969, Martha Lovato passed away from renal failure due to complications of lupus. Martha was 18 years old and survived only two years following her diagnosis. At the time, Martha’s disease was still a mystery to many physicians and researchers. Her treatment options were limited. In fall 2004, after an unprecedented battle with shingles…
Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Advancing the understanding of autoimmune diseases has implications for precision medicine, according to Robert Carter, MD, of the NIH. Research funded through the NIH’s Accelerating Medicines Partnership has the potential to develop better biomarkers and clinical trials for lupus and RA, paving the way for more personalized treatment…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 125
- Next Page »